Norgine Pharmaceuticals Limited. Norgine House, Widewater Place, Moorhall Road, Uxbridge, Middlesex, UB9 6NS. Company number 03527131.

01895 826600
http://norgine.co.uk/

© Copyright Norgine 2019
Policies

Footer smpc link
TARGAXAN smpc

Product under licence from Alfasigma S.p.A. TARGAXAN is a registered trademark of the Alfasigma group of companies, licensed to the Norgine group of companies.

NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
Zerif Lite Developed by ThemeIsle

Costing Details

Inpatient costs were estimated in UK£ at 2013/14 prices from published NHS sources at a mean cost of £513 per day for non-elective admissions for liver disease.1

Rifaximin-α drug costs were calculated from the price published in the British National Formulary of £259.23 for 56 550mg tablets2, giving an annual drug treatment cost per patient of £3,379 for the licensed dose of 550mg twice daily.

 

References

  1. NHS reference costs. Available from: www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014, 2013-14
  2. Joint Formulary Committee. British National Formulary. August 2015 ed. London: BMJ Group and Pharmaceutical Press; 2015
Seven UK participating centres agreed a standardised data collection pro-forma. Patients with chronic liver disease who were treated with rifaximin-α for secondary prevention of overt hepatic encephalopathy (OHE) were included.* Details of all causes of HE and emergency hospital admissions were requested at 3, 6 and 12 months before and after rifaximin-α initiation. Clinical data were recorded at baseline, at 3, 6 and 12 months before and after rifaximin-α initiation.
87% of patients (n=282) were taking concomitant lactulose.
*Some patients included were on 3 x 400 mg daily as this was prior to the launch of the UK licensed dose of TARGAXAN® 550 mg twice a day.

References

  1. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  2. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792
  3. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792 Supplementary Material